Gina Mauro

ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.

Perioperative nivolumab led to a significant improvement in event-free survival in the phase 3 CheckMate 77T trial in patients with stage III N2 and stage III non-N2 non–small cell lung cancer.

Zanidatamab therapy led to confirmed responses, disease control, and favorable overall survival in pretreated HER2+ biliary tract cancer in an update of the HERIZON-BTC-01 trial.

Over 8 years, dabrafenib and trametinib showed improved survival vs placebo in stage III melanoma, but overall and melanoma-specific benefits were not statistically significant.

Findings from the DUO-E study support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Camrelizumab, nab-paclitaxel, and cisplatin showed statistically significant enhancements in pathologic complete responses in patients with resectable locally advanced esophageal squamous cell carcinoma.

An unprecendented survival benefit was demonstrated with dostarlimab plus in patients with microsatellite instability-high primary advanced or recurrent endometrial cancer.

Promising survival data for Orca-T was also matched in a population of patients with hematologic malignancies aged 55 years and older.

Pembrolizumab with lenvatinib continued to demonstrate antitumor activity and led to longer survival rates vs historical controls in patients with advanced non–clear cell renal cell carcinoma.

Neoadjuvant camrelizumab in combination with nab-paclitaxel and cisplatin exhibited enhanced pathological complete response compared to solitary chemotherapy in individuals diagnosed with esophageal squamous cell carcinoma.

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor-naive myelofibrosis.

Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

The early adoption of ctDNA into the clinical workflow improves time to treatment, survival, and monitoring for patients undergoing molecular-based therapy.

A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.

mRNA-4157/V940 in combination with pembrolizumab improved recurrence-free survival in patients with high-risk melanoma.

In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.

Post-hoc analysis results showed a reduction in spleen volume of 35% with ruxolitinib in patients with myelofibrosis.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.

The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.

Novel treatments are needed to replace transplant and prevent graft-vs-host disease in order to improve patient outcomes.

Regardless of prior therapies, brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, according to subgroup analyses of the phase 3 ZUMA-3 trial.

The combination of zolbetuximab and mFOLFOX6 prolonged survival in patients with CLDN18.2+ advanced gastric gastroesophageal junction adenocarcinoma, according to the phase 3 data from the SPOTLIGHT trial.

Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.